ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,446.68
-1.37%
Dow Jones
40,347.97
-1.21%
US Dollar vs MXN
18.93555
1.57%
Brent Oil
79.97
-1.89%
Bitcoin
65,350.02
1.16%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. Johnson and Johnson (JNJ)

  7. Johnson and Johnson (JNJ) Noticias

JNJ

Johnson and Johnson (JNJ)

Johnson and Johnson
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NYSE:JNJ
FechaHoraFuenteTítuloSímboloCompañía
30/07/202420:06Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNYSE:JNJJohnson and Johnson
30/07/202417:42PR Newswire (US)DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligibleNYSE:JNJJohnson and Johnson
30/07/202405:00IH Market NewsToyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom ChatbotsNYSE:JNJJohnson and Johnson
29/07/202415:00Business WireJohnson & Johnson to Participate in the 2024 Wells Fargo Healthcare ConferenceNYSE:JNJJohnson and Johnson
26/07/202408:38Business WireCourts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step PlanNYSE:JNJJohnson and Johnson
26/07/202408:05Business WireFINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation PlanNYSE:JNJJohnson and Johnson
26/07/202405:07IH Market NewsAlphabet Unveils AlphaProof and AlphaGeometry 2; OpenAI Tests SearchGPT; Apple Loses Market Share in ChinaNYSE:JNJJohnson and Johnson
25/07/202415:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:JNJJohnson and Johnson
23/07/202415:00Business WireJohnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNYSE:JNJJohnson and Johnson
22/07/202410:59Business WireLawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy PlanNYSE:JNJJohnson and Johnson
22/07/202407:00PR Newswire (US)Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depressionNYSE:JNJJohnson and Johnson
17/07/202407:14Edgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
17/07/202405:30IH Market NewsTech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory DropNYSE:JNJJohnson and Johnson
17/07/202405:28IH Market NewsSpirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings UpdatesNYSE:JNJJohnson and Johnson
17/07/202405:25Business WireJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2024NYSE:JNJJohnson and Johnson
17/07/202405:20Business WireJohnson & Johnson reports Q2 2024 resultsNYSE:JNJJohnson and Johnson
11/07/202406:30Business WireJohnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26NYSE:JNJJohnson and Johnson
09/07/202416:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
03/07/202407:00PR Newswire (Canada)Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNYSE:JNJJohnson and Johnson
03/07/202407:00PR Newswire (Canada)Santé Canada autorise le traitement par RYBREVANT® (amivantamab) en association avec le carboplatine et le pemetrexed comme seul traitement de première intention ciblé approuvé pour les patients atteints d'un cancer du poumon non à petites cellules pNYSE:JNJJohnson and Johnson
02/07/202406:30PR Newswire (US)CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 studyNYSE:JNJJohnson and Johnson
28/06/202410:30PR Newswire (US)Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patientsNYSE:JNJJohnson and Johnson
27/06/202417:46Business WireLawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in PurdueNYSE:JNJJohnson and Johnson
21/06/202406:30Business WireJohnson & Johnson Completes Acquisition of Proteologix, Inc.NYSE:JNJJohnson and Johnson
20/06/202415:30PR Newswire (US)Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's diseaseNYSE:JNJJohnson and Johnson
20/06/202412:07Business WireMore than 60 Law Firms Oppose J&J Prepack Bankruptcy SchemeNYSE:JNJJohnson and Johnson
20/06/202407:00PR Newswire (US)TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous inductionNYSE:JNJJohnson and Johnson
20/06/202405:55IH Market NewsTrump Media Resells Stocks and Warrants; KB Home Exceeds Q2 Expectations, and More NewsNYSE:JNJJohnson and Johnson
17/06/202416:55Business WireBeasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc ProductsNYSE:JNJJohnson and Johnson
17/06/202407:00PR Newswire (US)Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancerNYSE:JNJJohnson and Johnson
 Showing the most relevant articles for your search:NYSE:JNJ

Su Consulta Reciente

FX
EURMXN
Euro vs MXN
NASDAQ
TSLA
Tesla
USOTC
ADDYY
Adidas (QX)
FX
EURUSD
Euro vs US Dollar
NYSE
VZ
Verizon Communications
NASDAQ
NVDA
NVIDIA
COIN
SOLUSD
Solana
NYSE
CVX
Chevron
FX
USDMXN
US Dollar vs MXN
COIN
ETHUSD
Ethereum
USOTC
BASFY
BASF (QX)
USOTC
RHHBY
Roche (QX)
AMEX
XLF
Financial Select Sector
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados